Literature DB >> 26823029

Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.

Akane Nogami1, Mineo Yamazaki, Yuko Saito, Hiroyuki Hatsuta, Yoshio Sakiyama, Masaki Takao, Kazumi Kimura, Shigeo Murayama.   

Abstract

Diagnosing clinical progressive supranuclear palsy (PSP) is challenging. We hypothesize that there are more cases of pathological PSP than have been clinically identified, but its diagnosis is challenging because the initial lesions and progression of PSP have not yet been clarified. The purpose of our study was to clarify the incidence of PSP in consecutive autopsy cases and identify pathological characteristics of early PSP. We investigated 324 consecutive autopsy patients from a general geriatric hospital (age, mean±SD=82.5±8.7 years). Paraffin sections of the midbrain were immunostained with anti 4-repeat tau antibodies (RD4). We selected cases showing RD4-positive neurofibrillary tangles and tufted astrocytes in the midbrain sections. Then, we used anti-phosphorylated tau antibody to immunostain sections from the basal ganglia, subthalamic nucleus, midbrain, pons, medulla, and cerebellum. Of the 324 patients, 35 had RD4-positive structures in the midbrain. From these 35 cases, we excluded those for which autopsies confirmed definite PSP (n=5) and cases of corticobasal degeneration (n=1), Alzheimer's disease (n=11), dementia of grain (n=10), and neurofibrillary tangles predominant forms of senile dementia (n=2), leaving 8 cases. We diagnosed these 8 cases as pure PSP-type tauopathy. Pure PSP-type tauopathy was detected in 2.5% of the consecutive autopsy cases, and this incidence was 1.6 times greater than that of neuropathologically definite PSP. This pure PSP-type tauopathy likely indicates preclinical stages of PSP. Furthermore, the novel neuropathological finding, which we term "preclinical PSP," is unique and has not previously been reported. In order to elucidate the causes and pathological mechanisms of PSP, preclinical PSP should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26823029     DOI: 10.1272/jnms.82.266

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  10 in total

Review 1.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

2.  Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD.

Authors:  John L Robinson; Ning Yan; Carrie Caswell; Sharon X Xie; EunRan Suh; Vivianna M Van Deerlin; Garrett Gibbons; David J Irwin; Murray Grossman; Edward B Lee; Virginia M-Y Lee; Bruce Miller; John Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  2020-03-01       Impact factor: 3.685

3.  Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old.

Authors:  Thomas G Beach; Michael Malek-Ahmadi
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

4.  Distribution patterns of tau pathology in progressive supranuclear palsy.

Authors:  Gabor G Kovacs; Milica Jecmenica Lukic; David J Irwin; Thomas Arzberger; Gesine Respondek; Edward B Lee; David Coughlin; Armin Giese; Murray Grossman; Carolin Kurz; Corey T McMillan; Ellen Gelpi; Yaroslau Compta; John C van Swieten; Laura Donker Laat; Claire Troakes; Safa Al-Sarraj; John L Robinson; Sigrun Roeber; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Günter U Höglinger
Journal:  Acta Neuropathol       Date:  2020-05-07       Impact factor: 17.088

Review 5.  Frontrunner in Translation: Progressive Supranuclear Palsy.

Authors:  Ali Shoeibi; Nahid Olfati; Irene Litvan
Journal:  Front Neurol       Date:  2019-10-22       Impact factor: 4.003

6.  LC3/FtMt Colocalization Patterns Reveal the Progression of FtMt Accumulation in Nigral Neurons of Patients with Progressive Supranuclear Palsy.

Authors:  Zulzikry Hafiz Abu Bakar; Jean-Pierre Bellier; Daijiro Yanagisawa; Tomoko Kato; Ken-Ichi Mukaisho; Ikuo Tooyama
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

7.  Parkinson's disease with a typical clinical course of 17 years overlapped by Creutzfeldt-Jakob disease: an autopsy case report.

Authors:  Shin-Ichiro Kubo; Tomoyasu Matsubara; Takeshi Taguchi; Renpei Sengoku; Atsuko Takeuchi; Yuko Saito
Journal:  BMC Neurol       Date:  2021-12-10       Impact factor: 2.474

8.  Anatomic survey of seeding in Alzheimer's disease brains reveals unexpected patterns.

Authors:  Barbara E Stopschinski; Kelly Del Tredici; Sandi-Jo Estill-Terpack; Estifanos Ghebremdehin; Fang F Yu; Heiko Braak; Marc I Diamond
Journal:  Acta Neuropathol Commun       Date:  2021-10-11       Impact factor: 7.801

9.  Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution?

Authors:  Javier Sánchez-Ruiz de Gordoa; Victoria Zelaya; Paula Tellechea-Aramburo; Blanca Acha; Miren Roldán; Carlos López-Molina; Valle Coca; Arkaitz Galbete; Maite Mendioroz; M Elena Erro
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

Review 10.  Clinical Spectrum of Tauopathies.

Authors:  Nahid Olfati; Ali Shoeibi; Irene Litvan
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.